ArticleJournal of travel medicine2024
Protection of natural infection against reinfection with SARS-CoV-2 JN.1 variant.
Article in Journal of travel medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Meta-analysis of hybrid immunity to mitigate the risk of Omicron variant reinfection.Frontiers in public health · 2024Pooled it
- Infection-acquired protection against SARS-CoV-2 infection and clinical severity by number of prior infections.Nature communications · 2026Article
- Global Estimates of COVID-19 Morbidity and Mortality: A Cohort Study and Mathematical Model Analysis.Influenza and other respiratory viruses · 2025Article
- Effectiveness and durability of a fourth dose of ancestral-strain mRNA vaccines against SARS-CoV-2 infection: a nationwide matched cohort study in Qatar.Scientific reports · 2025Article
- Immune histories and natural infection protection during the omicron era.Communications medicine · 2025Article
- Protection conferred by SARS-CoV-2 infection across a spectrum of reinfection symptoms and severities.BMJ open respiratory research · 2025Article
- SARS-CoV-2 Omicron XBB infections boost cross-variant neutralizing antibodies, potentially explaining the observed delay of the JN.1 wave in some Brazilian regions.IJID regions · 2025Article
- Evaluating Hospital Admission Data as Indicators of COVID-19 Severity: A National Assessment in Qatar.Open forum infectious diseases · 2025Article
- Fortifying defenses: Tactical safety protocols for COVID-19 sub-variant JN.1 in healthcare and laboratory settings.Journal of family medicine and primary care · 2025Article
- Article
- BNT162b2 Versus mRNA-1273 Vaccines: Comparative Analysis of Long-Term Protection Against SARS-CoV-2 Infection and Severe COVID-19 in Qatar.Influenza and other respiratory viruses · 2024Article
- Risk of COVID-19 in Children throughout the Pandemic and the Role of Vaccination: A Narrative Review.Vaccines · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.